Munich — Inter­na­tio­nal private equity inves­tor Bridge­point acqui­res a majo­rity stake in Phar­ma­Zell from DPE Deut­sche Private Equity and Maxburg Capi­tal Part­ners. The parties have agreed not to disc­lose the purchase price.

Phar­ma­Zell is a leading inde­pen­dent manu­fac­tu­rer of Active Phar­maceu­ti­cal Ingre­di­ents (API) in the highly stable and specia­li­zed API market. There, the company has a diver­si­fied port­fo­lio of more than 70 active ingre­di­ents and is an indus­try leader in a full range of products for the treat­ment of respi­ra­tory, inflamm­a­tory and liver dise­a­ses driven by life­style chan­ges. Many of the company’s products require special treat­ment proces­ses and/or tech­no­lo­gies. Phar­ma­Zell, head­quar­te­red in Raub­ling (near Munich), opera­tes four state-of-the-art produc­tion and R&D sites in Germany, Italy and India and employs over 900 people worldwide.

Bridge­point mana­ges more than €29 billion in assets provi­ded by global inves­tors. These include public and private pension funds, asset mana­gers, family offices, inde­pen­dent autho­ri­ties and insu­rance compa­nies around the world.

Advi­sors Phar­ma­Zell: P+P Pöllath + Part­ners advi­sed the manage­ment around CEO Oliver Bolzern.
Dr. Bene­dikt Hohaus (Part­ner, Lead Part­ner, MPP, M&A/Private Equity)
Dr. Roman Sten­zel (Coun­sel, MPP, M&A/Private Equity)
Silke Bande­ner (Asso­ciate, MPP, M&A/Private Equity, all Munich)